Crucell « Terug naar discussie overzicht

Draadje OT, bijzaken & geleuter in de marge! - Deel 2

1.200 Posts, Pagina: « 1 2 3 4 5 6 7 ... 56 57 58 59 60 » | Laatste
[verwijderd]
0
danicole
0
Ze doen er ook alles aan om te zorgen dat de economen ongelijk krijgen!

"Naast de werkloosheid werden ook de werkgelegenheidscijfers gerapporteerd. Over oktober kwamen er 92.000 banen bij, waar economen hadden gerekend op een toename met 133.000. Over de maand september werd het cijfer herzien van een banengroei van 51.000 tot 148.000".

Even zien: verwachting is 133.000 banen,zijn er eigenlijk 189.000 uhm nee da's teveel...schuiven we gewoon 97.000 terug naar september (toen zaten die sukkels er ook al naast) en hebben we in september 148.000 (ipv 51.000) en blijven er voor oktober 92.000 over. Waar hadden de economen ook al weer op gerekend ? 133.000 ?? Nee, zitten ze zo,n 40.000 te hoog met hun verwachting, duidelijk teken dat er een rem op de economische groei zit ... ?!?!?

"De werkloosheid daalde in oktober onverwacht naar 4,4%, tegen een gemiddelde economenverwachting van 4,6%. Daarmee kwam de werkloosheid op het laagste niveau in vijf jaar."

"In de Verenigde Staten is het aantal wekelijkse aanvragen voor een werkloosheidsuitkering in de week tot en met 28 oktober 2006 met 18.000 gestegen naar 327.000. Dit heeft het Amerikaanse Labor Department donderdag bekendgemaakt.

In de voorgaande week kwam het aantal aanvragen uit op een herziene 309.000, tegenover een eerder gemeld aantal van 308.000. Economen gingen ervan uit dat het aantal aanvragen voor een werkloosheidsuitkering in de week tot en met 28 oktober zou zijn uitgekomen op 310.000.

Het vierwekelijks voortschrijdend gemiddelde kwam uit op 311.250"

En ze blijven er maar naast zitten...
[verwijderd]
1
Your Genes May Hold Key to How Sick You Get from the Flu

11/03/06 -- With lessons from the 1918 flu pandemic in the rearview mirror and the avian flu a looming obstacle in the road ahead, researchers from Southern Illinois University School of Medicine are trying to understand why a flu virus kills some people but not others.

With the help of some high tech equipment, well-defined mouse models and lots of analytical know how, physiologists are beginning to hone in on the secret to this differential response. It-s probably in the genes - and the proteins they encode.

Two studies to be presented at The American Physiological Society conference "Physiological Genomics and Proteomics of Lung Disease" have found that a strain of mice that is more likely to die of influenza infection mounts a dramatically enhanced immune response in the lungs compared to a strain of mice that generally develops milder disease.

The long-term goal of these studies is to identify genes that control the individual variation in inflammation during influenza infection. This information could ultimately help identify those most at risk to develop severe disease and die from the flu, and help doctors direct vaccines, anti-viral and anti-inflammatory medications to those who need them most.

The researchers will present the study "Inflammatory responses in inbred mice with different susceptibility phenotypes to Influenza A virus infection," on Nov. 3. The study was carried out by Rita Trammell and Linda Toth of the Southern Illinois University School of Medicine, Springfield, Ill. The conference takes place Nov. 2-5 in Fort Lauderdale.

Lessons from 1918

"Flu epidemics typically kill the very old and the very young. But the 1918 epidemic killed millions around the world, including many healthy young adults. The healthy immune systems of young adults produced an overly strong immune response that resulted in severe inflammation of the lungs. Similar to the 1918 pandemic virus, most H5N1 avian influenza virus infections occur in young adults with no pre-existing medical conditions," Trammell noted.

"The recent emergence of the highly pathogenic H5N1 influenza virus has raised international concerns that continued evolution of the virus could cause a pandemic with global health and economic consequences," Trammell said. "Should this occur, the ability to identify those at highest risk for developing severe disease may help to determine who would benefit most if vaccines and anti-viral therapeutics are in limited supply," she said.

"Studies to date have focused on the virus itself to determine what makes some viruses killers," she said. "Our research looks at the role of the host-s genetic background, an area that has remained largely unexplored."

Flu fells some, not others

Trammell and Toth infected two strains of laboratory mice with an Influenza A virus. "Our previous studies established that if you give the same dose of influenza A virus to both strains of mice, about half of the BALB/cByJ (Type B) mice will die, compared to about 10% of the C57BL/6J (Type C) mice," Trammell said.

The researchers studied the early immune response by examining the lung tissues of mice 30 hours after they were infected. They measured the amount of virus, cytokines and myeloperoxidase that was present in the lungs.

Cytokines and myeloperoxidase are proteins that function in the immune response. Some cytokines are pro-inflammatory, that is, they cause inflammation that helps to eliminate the pathogen. In a well-orchestrated immune response, pro-inflammatory cytokines act first and then recede once the virus is eliminated. Anti-inflammatory cytokines regulate the immune response to minimize damage to normal tissues. Myeloperoxidase is an enzyme that indicates the number of neutrophils -- a type of white blood cell -- present in the lung.

Inflammation of lungs is the difference

The researchers found the level of virus in the lungs of the two mouse strains did not differ significantly. However, all the pro-inflammatory cytokines, with one exception, were significantly higher in the Type B (disease susceptible) mice when compared to Type C (disease resistant) mice.

"Although viral titers are equivalent, B mice develop a much greater pro-inflammatory response during influenza infection than C mice, which may contribute to the differential mortality in these strains," the authors concluded.

A related study, "Microarray analysis of gene expression in the lungs of influenza-infected C57BL/6J and BALB/cByJ mice," complemented these findings. In this study, Toth and fellow Southern Illinois University School of Medicine researcher, Ming Ding, examined what happened to immune-related messenger RNA (mRNA) levels after the two mouse strains were exposed to the flu. The immune-related mRNAs evaluated in this study ultimately produce the proteins important to the immune response.

Like the other study, these researchers found no difference in the amount of virus in the lungs of the two mouse strains after influenza infection. But they were "amazed at the difference in immune-related mRNA levels between the two strains," Trammell said. When compared to uninfected control mice, the mRNA levels in Type B mice were on average 24 times higher, with some types of mRNA increasing more than 100 fold. In contrast, mRNA levels in Type C mice only increased less than 3-fold after infection.

"Both studies show clear and dramatic differences in the pulmonary inflammatory response of the Type B strain of mice, as compared with Type C strain, after infection with the same dose of influenza virus," Trammell said. "These distinctive responses to the identical virus challenge suggest that the genetic control of the inflammatory response differs between these two strains."

Toth and Ming will present their study at the conference on Nov 3.

"Our long-term goal is to identify genomic regions, genes, and alleles that control variation in inflammation during infection with influenza virus," Trammell said. "The identification of these genomic regions has enormous implications for understanding and avoiding the fatality associated with infection."

These studies are at the cutting edge of proteomic and genomic research, which has taken a big leap with recent advances in imaging technology and new methods of analyzing masses of data.

Funding

The research was funded by the National Institutes of Health.

Source: American Physiological Society

gogogoo
0
Goed nieuws voor CF patienten:

Immune Proteins Give Clues to Cystic Fibrosis
Three show up in CF patients in unique way, researchers say

FRIDAY, Nov. 3 (HealthDay News) -- British scientists have discovered a possible link between certain proteins and cystic fibrosis, a genetic disease that attacks the lungs and other organs and significantly shortens life expectancy.

The University of Sheffield researchers found a highly unusual distribution of the proteins -- SPLUNC1, SPLUNC2 and LPLUNC1 -- in the lungs and airways of cystic fibrosis patients. The proteins are believed to play a role in the immune system.

The finding could improve scientists' understanding about the immune system's role in cystic fibrosis and about how the disease progresses.

In this study, the researchers compared lung tissue from 21 cystic fibrosis patients to healthy lung tissue from 10 other people.

"Our results show unique expression domains for (the proteins) within the airways and suggest that alterations in expression of these putative innate immune molecules may be associated with lung disease," the study authors wrote.

"We've shown these proteins to be expressed in places like the upper airways, nose and mouth, where many bacteria and infectious agents are found," Lynne Bingle, of the School of Clinical Dentistry at the University of Sheffield, said in a prepared statement.

It's believed that these proteins are part of the first line of the body's defenses against infectious agents, she said.

The study was to be presented Friday at a meeting of the American Physiological Society in Fort Lauderdale, Fla.

More information

The March of Dimes has more about cystic fibrosis.
[verwijderd]
0
Imagine If Killing Flu Viruses And Other Microbes Were As Simple As Turning On A Light
Main Category: Flu / SARS News
Article Date: 04 Nov 2006 - 12:00pm (PST)


Exposing a unique surface coating to light may in fact hold the key to protecting you from virtually all viruses and bacteria, including the feared avian flu.

Laboratory testing of a novel, permanent nano-coating, developed in collaboration by researchers at North Carolina State University College of Textiles and Emory University School of Medicine, has been shown to kill or inactivate most viruses and bacteria when exposed to visible light. Early tests have shown that the coating kills 99.9 percent of influenza viruses and 99.99 percent of vaccinia virus, which causes rash, fever, head and body aches.

The coating technology was developed by Dr. Stephen Michielsen, associate professor in NC State's College of Textiles, and Drs. Igor Stojiljkovic and Gordon Churchward, associate professors at Emory University's School of Medicine in Atlanta.

NC State has applied for a patent on the invention, which has been licensed to Research Triangle Park-based start-up LaamScience, Inc. The company - whose name stands for Light Activated Anti Microbials - has raised more than $400,000 in seed financing from North Carolina angel investors that will enable it to optimize the coating and begin developing product prototypes.

Prototypes will be used in performance trials targeting hospital areas including waiting rooms. The company is also developing a room air purifier that incorporates its nano-coated filter technology. Other potential application areas include anti-viral filter systems for airplanes and businesses, as well as for a variety of uses for first responders and the military, including anti-viral masks. Perhaps equally important, the invention may be used to make everyday objects resistant to viruses and bacteria in the presence of light.

"We have many exciting opportunities to use these proprietary coatings to stop infection before it causes disease and death," says Tom Roberg, chief executive officer of LaamScience. "The technology developed at NC State and Emory University provides a huge opportunity to impact the health and welfare of people throughout the world."

The invention grew out of Michielsen's research into nanotechnology and its use to modify the surface of polymers and fibers. The thin coating is a type of dye that can be applied to the surface of all types of fabrics and materials. When exposed to light, the coating acts as a photo catalyst, sparking a chemical reaction with air and killing most viral and bacterial microbes.

"In the presence of light, a specific reaction takes place on the surface that makes the air poisonous to the microbes, yet harmless to people," Michielsen says. "The coating doesn't wear out and continually regenerates so it's able to continue killing viruses again and again."

Michielsen presented the results of his coating research last fall as part of the Achieve More Field Day series, which is organized by the NC State's Office of Extension, Engagement and Economic Development. The Achieve More Field Day invites industry executives, venture capitalists and science and technology entrepreneurs to campus to learn more about NC State's research, resources and partnership opportunities. Roberg heard Michielsen's presentation and approached him and the university about licensing, patenting, and commercializing the coating technology.

"This is an outstanding example of how quickly breakthrough research results can be brought to market when the right conditions are present," said Dr. A. Blanton Godfrey, dean of the College of Textiles. "NC State's continuing focus on economic development coupled with our traditional land-grant mission creates the right atmosphere for bringing leading researchers together with entrepreneurs. The potential economic benefit to the Triangle area and state is only overshadowed by the potential benefit to the health of our and the world's population."

LaamScience's headquarters and laboratory are in the Becton Dickinson Technologies' incubator space in Research Triangle Park, where the company will develop the coating technology for commercial uses.

"The potential uses for this technology are unlimited," says Dr. Patrick Mize, LaamScience's chief science officer. "These are applications that can change the world."

###
[verwijderd]
0
New Drug Discovery Technology From South American Rain Forests
Main Category: Biology / Biochemistry News
Article Date: 04 Nov 2006 - 11:00am (PST)


A British drug discovery company which has developed the world's fastest drug profiling system has joined forces with a Brazilian company to seek new medicines from the South American rain forests.

At a time when the number of new drugs in the world's development pipeline has dwindled, the British company e-Therapeutics has formed a partnership with Brazilian company Grupo TCI to establish a joint research facility close to the Amazonian and Atlantic rain forests, to start testing substances from the millions of plants in the most diverse ecosystem on the planet.

New medicines are needed to combat a range of diseases which threaten to reach pandemic levels, including drug-resistant strains of tuberculosis and virus infections like avian flu. New drugs are also being sought for tropical diseases which occur in Brazil, such as hepatitis C, Chagas disease and Leishmaniasis.

In a separate deal, e-Therapeutics is joining forces with CURA, a pharmaceutical consortium backed by the Brazilian Government, which is establishing a cluster of drug discovery, development and marketing industries in North East Brazil. This will give e-Therapeutics a base from which to access to Brazilian pharmaceutical companies.

e-Therapeutics was spun out of Newcastle University in 2003 by Professor Malcolm Young, who developed new 'systems biology' techniques which can accurately predict the biological effect of any substance on any human tissue and on pathogens, such as bacteria and viruses. He attracted more than 10m pounds research funding from the Engineering and Physical Sciences Research Council and other organisations to turn his ideas into practice.

Professor Young demonstrated the effectiveness of its technology by correctly predicting the effects of known drugs, such as 103 known antibiotics. But it also uncovered unknown antibiotics, which are now entering drug development.

e-Therapeutics is not alone in hunting for rain forest medicines but has the advantage of a system which typically takes only two weeks to assess a substance, as opposed to two years by conventional processes.

Professor Young, who is now Pro-Vice-Chancellor at Newcastle University, said: 'This is a fantastic opportunity to investigate Brazil's colossal biodiversity with our cutting edge technology. There is enormous potential for drug discovery in the rain forests, where there are millions of plant species, many of which produce bioactive chemicals.'

Roberto Marinho Filho, President of Grupo TCI, said: 'This new partnership will enable us to access our rich resource of natural compounds and, through e-Therapeutics novel technology, determine the medical use of these natural compounds. This will open the current bottlenecks in developing new drugs. We will be using the world's fastest compound profiling system, so the process of discovery of medicines, which can reduce the two years required currently for these processes to about two weeks.'

e-Therapeutics was able to link up to the Brazilian companies with the assistance of the North East Process Industry Cluster (NEPIC), an organisation formed by the 200 Pharmaceutical, Biotechnology, Speciality, Commodity and Petrochemical companies based in the North East of England. NEPIC says that it intends to provide industrial connections and support for e-Therapeuitics as it grows. Funding for e-Therapeutics has included a £90,000 investment from NStar, an independent early stage technology venturing company, via its Proof of Concept Fund (POC) in 2004. This helped to accelerate the development of e-Therapeutics by financing research and demonstrating the company's capabilities in the pharmaceuticals and biotechnology markets.

###

Contact: Professor Malcolm Young
University of Newcastle upon Tyne
[verwijderd]
0
Goedenavond allemaal,

Vanavond in de Quote 500 nog een verhaaltje over Aat van Herk gelezen, heb hier nog niet eerder gezien.

Er staat dus geschreven dat van Herk besloten heeft zijn investeringsdrift te richten op biotechnologie en dat hij hard op weg is de "godfather" van de Nederlandse biotechindustrie te worden met een uitgebreid belang van meer dan 10% in Crucell en Pharming.

Groet,

Truco
[verwijderd]
0
They are going to have to go out, be aggressive and buy smaller companies."

Toch geen Crucell hopelijk"????

Report: AstraZeneca feels pressure
Shareholders want drug development pipeline to improve, British newspaper says
By GARY HABER, The News Journal

Posted Saturday, November 4, 2006
After repeated setbacks, several large shareholders of AstraZeneca PLC want the drug maker to ramp up spending to bolster its drug development pipeline.

The shareholder pressure, originally reported in The Times of London newspaper on Friday, comes about a week after the British pharmaceutical giant, whose U.S. headquarters is in Fairfax, said it would stop development of stroke drug NXY-059. The drug, formerly called Cerovive, failed to significantly reduce stroke-related disability in a late-stage clinical trial.

"The obvious question to ask is, 'What are you going to do about the pipeline?' " Gareth Powell, a fund manager at AXA Framlington in London, which owns 15 million AstraZeneca shares, or about 1 percent of the company, told The Times. "They are going to have to go out, be aggressive and buy smaller companies."

The newspaper also reported that company officials, including chief executive David Brennan, plan to meet with some of the largest shareholders later this month.

Steve Brown, an AstraZeneca spokesman, said Friday that company officials meet regularly with large investors, and the company is committed to new drug development both through its own research and development efforts, and through "external opportunities."

"Our strategy going forward is that research and development is our No. 1 priority," Brown said.

To help fill a pipeline considered by some among the weakest in the industry, AstraZeneca has turned to acquisitions and partnerships with biotechnology companies and smaller drug companies.

In the past 12 months, the company has announced a flurry of licensing deals and acquisitions, including the $1.07 billion purchase of British biotechnology company Cambridge Antibody Technology Group, and a deal to buy KuDOS Pharmaceuticals, a British cancer drug developer, for $210 million.

AstraZeneca also announced in December it would pay Alpharetta, Ga.-based AtheroGenics Inc. up to $1 billion for development rights to AGI-1067, a treatment for atherosclerosis, or hardening of the arteries.

The drug, which is in late-stage clinical trials, is one that the company is counting on to help fuel growth following the decision to drop development of NXY-059 and earlier moves to halt development of two other drugs once considered possible blockbusters for the company: Exanta, a blood thinner, and Galida, for the treatment of diabetes.

AGI-1067 sales could top $5 billion a year by 2017, Gbola Amusa, an analyst with Sanford C. Bernstein & Co., said in a note to clients last month.

Biotech companies have been able to command top dollar as big pharmaceutical businesses scramble to acquire them to supplement their drug development pipelines, said John McCamant, editor of the Medical Technology Stock Letter in Berkeley, Calif.

"We're seeing a lot more activity, and it seems like the pace is picking up," McCamant said.

Last month Merck & Co. agreed to pay $1.1 billion to acquire Sirna Therapeutics Inc., and Eli Lilly & Co. announced a $2.1 billion deal for Icos Corp., with which it has a joint venture to market Cialis, a drug for erectile dysfunction.

Clinical trial

In a separate development, AstraZeneca said Friday it was adding a 480-patient clinical trial for development of CytoFab, a drug for the treatment of severe infections, which the company licensed from British company Protherics PLC for up to $341 million. The 21-month clinical trial, which will start in the second half of next year, will lengthen the amount of time it would take to bring the drug to market. But, it could also help shorten the time needed for late-stage clinical trials, AstraZeneca said.

AstraZeneca's U.S. shares fell 66 cents, to $60.60, in New York Stock Exchange trading Friday.

Contact Gary Haber at 324-2878 or ghaber@delawareonline.com.
[verwijderd]
0
Invasive Brain Cells Killed By New Cancer-Fighting Virus
Main Category: Cancer / Oncology News
Article Date: 03 Nov 2006 - 23:00pm (PST)



Researchers funded by The Terry Fox Foundation and the Canadian Cancer Society have found that a cancer-fighting virus called VSV kills the most malignant form of brain cancer in mice.

The team also discovered that the virus can be given intravenously and targets invasive tumour cells.

The research team first modified the virus by altering one of the genes to make it safer in normal cells but still able to kill cancer cells. They then used a new way of delivering the virus - intravenously instead of directly into the tumour - and were able to target the main tumour as well as the tumour cells that had spread from the main mass.

The study was led by Dr. Peter Forsyth, a medical oncologist with the Alberta Cancer Board and a professor of oncology, neurosciences, biochemistry and molecular biology at the University of Calgary. The study is published in the Nov. 1 issue of the Journal of the National Cancer Institute.

The brain tumour cells that invade into the surrounding normal brain are usually "hidden" from current treatments and are the ones that usually lead to a disease recurrence. The research using the vesicular stomatitis virus (VSV) was conducted on mice as well as on tumour specimens from patients with an aggressive form of brain cancer called malignant glioma.

"These findings are an excellent example of the great value of scientific collaboration," says Darrell Fox, national director of The Terry Fox Foundation. "Dr. Forsyth is part of a pioneering group of researchers that are sharing their expertise and benefiting from the knowledge of others working in this exciting new area of anti-cancer treatment."

"Research into viruses that target cancer is a promising new avenue in the fight against this disease," says Dr. Barbara Whylie, CEO of the Canadian Cancer Society. "We look forward to the possibility of this research leading to more effective treatments for this devastating disease."

Despite dramatic advances in the treatment of malignant glioma, one of the most common types of nervous system cancers in adults, the prognosis of patients has not improved substantially in the past 30 years. While there is typically initial success in treatment, the cancer cells usually spread beyond the main tumour and the disease recurs in another part of the body. When this happens, the disease often becomes resistant to standard chemotherapy treatment.

"An ideal cancer-fighting virus should have effective delivery into multiple sites within the tumour, evade the body's immune responses, reproduce rapidly, spread within the tumour and infect cells that have spread. In this study, that's exactly what we found that VSV has done when injected intravenously," says Dr. Forsyth.

The researchers tested VSV on 14 cell lines of malignant glioma and found that the virus infected and killed all cell lines. The normal cell lines - those that did not contain malignant glioma cells - were not affected.

"One of the limitations to the use of these viruses in patients is the difficultly in getting a sufficient amount of virus to the cancer," says Dr. Forsyth. "While these are very early results, we are very encouraged to find that delivering VSV intravenously attacks the cancer cells and not normal cells. From a patient's point of view, it is obviously a lot easier to be treated with a few intravenous treatments rather than having several surgeries to inject the treatment directly into your brain."

In 2006, an estimated 2,500 Canadians will be diagnosed with brain cancer and 1,670 will die of it. Even with the best available treatments - usually surgery and chemotherapy or radiation - patients with malignant glioma survive, on average, just one year.

###

The Terry Fox Foundation's mission is to maintain the principles of Terry Fox while raising money for cancer research through the annual Terry Fox Run, memoriam donations and planned gifts. This year, the Foundation, through the National Cancer Institute of Canada, is funding $20 million in research across the country.

The Canadian Cancer Society is a national community-based organization of volunteers whose mission is to eradicate cancer and to enhance the quality of life of people living with cancer. It is the largest charitable funder of cancer research in Canada. This year, the Society is funding more than $47 million in leading-edge research projects across the country. When you want to know more about cancer, visit our website at www.cancer.ca/.

Alexa Giorgi

Contact: Nancy Rose
Alberta Cancer Board

[verwijderd]
0
Regeling stamceltransplantatie
Kamerstuk, 31-10-2006
De Voorzitter van de Tweede Kamer
der Staten-Generaal
Postbus 20018
2500 EA DEN HAAG
CZ/IZ/2726534
31 oktober 2006

Op 25 oktober 2006 heb ik de Regeling stamceltransplantatie vastgesteld, die u bijgaand aantreft.
Met de Regeling stamceltransplantatie zijn alle mogelijke soorten van stamceltransplantaties (dus ook stamceltherapie) onder het vergunningstelsel van de Wet op bijzondere medische verrichtingen (WBMV) gebracht. Daarbij wordt expliciet onderscheid gemaakt tussen hematopoietische stamceltransplantatie en stamceltherapie. Bij stamceltherapie geldt dat alleen de universitair-medisch centra en het NKI in aanmerking komen voor een vergunning en daarmee tot het doen van experimenten. Elk experiment moet voldoen aan de eisen die de Wet medisch-wetenschappelijk onderzoek met mensen (WMO) stelt. Dat houdt ondermeer in dat het onderzoeksvoorstel een positief oordeel moet hebben van de Centrale Commissie Mensgebonden Onderzoek (CCMO).
De Minister van Volksgezondheid, Welzijn en Sport,

H. Hoogervorst

www.minvws.nl/images/stamcel_tcm19-13...
[verwijderd]
0
Novartis plans lab in Shanghai
Investment reflects rise in incomes and health needs in China
By James Kanter / International Herald TribunePublished: November 5, 2006

PARIS: In one of the biggest investments by a major drug maker in China, the Swiss company Novartis plans to build a $100 million laboratory next year in Shanghai - another sign that the European pharmaceutical industry is casting its net far and wide for new medicines as innovation stagnates at home.

The research site will start operations in May and eventually employ 400 mainly Chinese scientists, the company was to announce Monday. Novartis will initially focus its research on the infectious causes of cancer, in particular on the link between liver cancer and hepatitis B, which is prevalent in the Chinese population.

"The level of scientific expertise in China is rising rapidly," said Dr. Daniel Vasella, chief executive of Novartis. "At the same time, the health care needs of the Chinese are growing, primarily the result of urbanization, lifestyle changes and associated chronic diseases."

Pharmaceutical companies large and small have been moving their research operations away from Europe, preferring to do much of their work in the United States where they find more abundant financing and a more dynamic community of scientists and engineers.

Novartis transferred its research headquarters to Cambridge, Massachusetts, from Switzerland in 2002. The move into China by Novartis is a signal that big drug makers are taking a major new step into Asia. Growing purchasing power in countries like China also means greater incidences of rich-world maladies like hypertension and diabetes as people take sedentary office jobs and eat higher-calorie diets.

Peter Behner, a drug industry expert at the consulting firm Booz Allen Hamilton, said other drug companies were likely to follow Novartis. "Opening a major research facility in China is a huge step," Behner said. "This is a 'me too' industry, and so the other major pharmaceutical companies will be in hot pursuit."

Pharmaceutical sales in China currently are worth about €3.2 billion, or $4.1 billion, a tiny fraction of the €450 billion global market. But with a population larger than the United States, Europe and Japan combined, China will be a source of exploding demand for medicines in years to come.

Tailoring products to prepare for the opening of the vast Chinese domestic market and other Asian markets is important for companies like Novartis. Developing treatments that draw on traditional Chinese remedies is likely to require local expertise.

But analysts have said that an important part of these companies' China strategy is to improve relations with local authorities who in the future will decide what medicines to buy for their citizens.

"I do believe that pharmaceutical companies are positioning to adequately lobby for reimbursement," Behner said. "If you create jobs, you create good will."

Another reason for the China focus is the country's large pool of lower-cost science graduates. Scientists with doctoral degrees can be paid as little as one-fifth of as much in China as similar personnel in the United States - an important factor when the major companies are spending more money on drug development but coming out with fewer blockbuster products than in the past.

"You can get skilled people for what would be in the West bargain-basement compensation," said Michael Tubbs, a consultant for the Department of Trade and Industry in Britain.

But Tubbs said that research operations in China were likely to remain limited, in part because of the weak patent and legal system, where copying of designs, code for software or formulas for new medicines is a major concern.

"Don't expect companies to move research and development wholesale into China for products with enormous competitive value worldwide," Tubbs said. Instead, companies are likely to limit their research so that "if a competitor got hold of it, it would not be company-destroying."

The investment Novartis will make in China puts the company more squarely in competition with Sanofi- Aventis, a French drug maker, which is ahead by sales in the big emerging economies of Brazil, Russia, China and India.

But markets for medicine sales are especially fragmented in these countries, and there is probably plenty of room for growth. Sanofi's share of those markets is 4.5 percent, compared with 4 percent for Novartis, according to 2005 data from IMS, a health information company.

Novartis makes generic medicines for the Chinese market through its subsidiary Hexal, and the company already had success using traditional Chinese medicine to produce a modern drug.

Coartem, a Novartis medicine that eases the symptoms of malaria and cures malaria infections, is derived from sweet wormwood plants grown in China and Africa and was developed with partners including the Chinese Academy of Military Medical Sciences.

But the medicine is never likely to be one of the company's big earners: about 95 percent of Coartem is offered at a heavy discount to governments of countries where malaria is widespread, and treatments are priced at about $1.

[verwijderd]
0
Iraq: Amnesty International deplores death sentences in Saddam Hussein trial


11/05/2006
Amnesty International deplores the decision of the Supreme Iraqi Criminal Tribunal (SICT) to impose the death sentence on Saddam Hussein and two of his seven co-accused after a trial which was deeply flawed and unfair. The former Iraqi dictator was sentenced today in connection with the killing of 148 people from al-Dujail village after an attempt to assassinate him there in 1982. The trial, which began in October 2005 almost two years after Saddam Hussein was captured by US forces, ended last July. The verdict was originally due to be announced on 16 October but was delayed because the court said it needed more time to review testimony.

The case is now expected to go for appeal before the SICT's Cassation Panel following which, if the verdict were to be upheld, those sentenced to death are to be executed within 30 days.

"This trial should have been a major contribution towards establishing justice and the rule of law in Iraq, and in ensuring truth and accountability for the massive human rights violations perpetrated by Saddam Hussein’s rule," said Malcolm Smart, Director of the Middle East and North Africa Programme. "In practice, it has been a shabby affair, marred by serious flaws that call into question the capacity of the tribunal, as currently established, to administer justice fairly, in conformity with international standards."

In particular, political interference undermined the independence and impartiality of the court, causing the first presiding judge to resign and blocking the appointment of another, and the court failed to take adequate measures to ensure the protection of witnesses and defence lawyers, three of whom were assassinated during the course of the trial. Saddam Hussein was also denied access to legal counsel for the first year after his arrest, and complaints by his lawyers throughout the trial relating to the proceedings do not appear to have been adequately answered by the tribunal.

"Every accused has a right to a fair trial, whatever the magnitude of the charge against them. This plain fact was routinely ignored through the decades of Saddam Hussein's tyranny. His overthrow opened the opportunity to restore this basic right and, at the same time, to ensure, fairly, accountability for the crimes of the past. It is an opportunity missed," said Malcolm Smart, "and made worse by the imposition of the death penalty."

Amnesty International will now follow closely the appeal stage, where the evidence as well as the application of the law can be reviewed, and the SICT has therefore an opportunity to redress the flaws of the previous proceedings. However, given the grave nature of these flaws, and the fact that many of them continue to afflict the current trial before the SICT, Amnesty International urges the Iraqi government to seriously consider other options. These could include adding international judges to the tribunal, or referring the case to an international tribunal -- an option indicated by the UN Working Group on Arbitrary Detention last September.

Saddam Hussein is currently being tried by the SICT, together with six others, on separate charges arising from the so-called Anfal campaign, when thousands of people belonging to Iraq's Kurdish minority were subject to mass killings, torture and other gross abuses in 1988.
news.amnesty.org/index/ENGMDE140372006
[verwijderd]
0
quote:

jan941 schreef:

Novartis plans lab in Shanghai

......the company was to announce Monday.

06/11/2006, 2006, 05.00 AM CET

Novartis creates new strategic biomedical R&D center in Shanghai

Integrated Research & Development center the first Novartis site of its kind in China
Primary focus on infectious causes of cancer endemic to China and Asia
Center will capitalize on talent in emerging life sciences cluster in Shanghai
Initial investment of USD 100 million to create Shanghai site - set to begin operations in May 2007
Shanghai, November 6, 2006 - Novartis announced plans today to build an integrated biomedical Research & Development center in Shanghai's Zhangjiang Hi-Tech Park that will become an integral part of the Group's global research and development network.
The establishment of this strategic site is a commitment by Novartis to conduct cutting-edge pharmaceutical research and development in China. It will also enable further expansion of the strong network of existing R&D alliances that Novartis has in China.
Research and development activities at the site will initially focus on addressing urgent medical needs in China and Asia, particularly infectious causes of cancer endemic to the region.
"The level of scientific expertise in China is rising rapidly. At the same time, the healthcare needs of the Chinese are growing, primarily the result of urbanization, lifestyle changes and associated chronic diseases," said Dr. Daniel Vasella Chairman and CEO of Novartis. "The Shanghai center will allow us to combine modern drug discovery approaches with those of traditional Chinese medicine that have been used to treat patients in China for thousands of years. This new research center will help Novartis contribute to the needs of patients in China and elsewhere and has the potential to become a global center for biomedical innovation."
Expansion of global Novartis R&D network
The center will become the eighth site within Novartis Research and Development network. It will be staffed primarily by scientists recruited from Shanghai's emerging cluster of innovative academic, biotech and pharmaceuticals research institutions.
Scientists will initially work in a 5,000 square meter start-up facility that is expected to open in May 2007. Construction of a permanent 38,000 square meter facility for approximately 400 scientists will begin in July 2007. An investment of USD 100 million has been planned for the design and construction of the two facilities.
Focus on diseases prevalent in China
An initial area of research will be infectious causes of cancer. One disease is liver cancer caused by the hepatitis viruses. Some one-third of the 400 million people infected with the hepatitis B virus are in China, with experts estimating that the virus kills 300,000 people in mainland China each year.
"Shanghai is clearly emerging as a new epicenter of science globally, and is a magnet for the best and the brightest investigators. It is a perfect location for exploring novel scientific approaches for the discovery of new medicines that will ultimately benefit patients in China and around the world," said Dr. Mark Fishman, President of the Novartis Institutes for BioMedical Research.
The site will also include an integrated exploratory development center that will closely collaborate with basic research and local academic centers to further develop the concept of mechanism-based medicine and leverage emerging new technologies.
"Our activities in the new R&D center will go far beyond conducting early clinical trials by expanding drug discovery with translational medicine principles enhanced with safety investigations, biomarker detection and bio-analytics as well as gene expression profiling. We aim to complement the search of useful and safe medicines with diagnostic tools to support local and global R&D efforts," said Dr. Jean Jacques Garaud, Global Head of Exploratory Development at Novartis Pharma AG.
Long-term commitment to China
Novartis and its predecessor companies have been active in China since 1938 when Ciba opened its office in Shanghai, initially entering the country as a provider of dyestuff and later expanding into pharmaceuticals through steady investments.
Novartis currently ranks as the fourth largest pharmaceutical company in the Chinese hospital market with a compound annual sales growth rate of over 30% during the last five years. In February 2006, construction began on a USD 83 million development and production plant in Changshu, Jiangsu Province, which is expected to open in mid-2007.
A series of important research collaborations have been fostered with Chinese partners. Novartis has a six-year research partnership with the Shanghai Institute of Materia Medica (SIMM) to identify and test traditional medicines for pharmacological properties. Collaborations have also been established with WuXi PharmaTech Co, Ltd., Chinese University of Hong Kong National Institutes of Biological Sciences (NIBS) and Kunming Institute of Botany.
www.novartis.com/
[verwijderd]
0
Thousands got parts stolen from cadavers
Transplanted tissues weren't screened
November 5, 2006
BY JIM RITTER Health Reporter More than a year after surgery to relieve her neck pain, Jaqueline Neumann received some disturbing news.
The bone fragment used to fuse two neck vertebrae came from a deceased donor who wasn't screened for HIV, hepatitis and other diseases.
"I could have a major health hazard on my hands," she said.
Neumann and thousands of others nationwide are living with transplanted bone fragments, tendons, heart valves, skin and other tissue that were harvested from East Coast funeral homes without screening for diseases and without families' permission. Doctors notified patients once the thefts were uncovered.
www.suntimes.com/lifestyles/health/12...,CST-NWS-bodyparts05.article
[verwijderd]
0
RTRS-Isotis wordt Amerikaans
LAUSANNE (ANP) - Het biotechnologiebedrijf Isotis heeft
besloten om Amerikaans te worden met één beursnotering, aan de
Amerikaanse technologiebeurs Nasdaq. De onderneming heeft
momenteel noteringen in Amsterdam, Zürich en Toronto.

Dat heeft Isotis maandag bekendgemaakt. Het bedrijf vindt
het een logische stap in zijn ontwikkeling. Ruim 90 procent van
de werknemers en meer dan drie kwart van de omzet komen uit de
Verenigde Staten.

((Joram Kanner, email economie(at)anp.nl, +31 20 504 5999))
1.200 Posts, Pagina: « 1 2 3 4 5 6 7 ... 56 57 58 59 60 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 882,27 -0,36 -0,04% 18:05
AMX 926,00 +11,58 +1,27% 18:05
ASCX 1.207,81 +9,07 +0,76% 18:05
BEL 20 3.886,76 +11,89 +0,31% 18:05
Germany40^ 18.128,90 -32,11 -0,18% 22:29
US30^ 38.368,53 +156,92 +0,41% 22:29
US500^ 5.114,78 +19,49 +0,38% 22:29
Nasd100^ 17.790,45 +92,36 +0,52% 22:29
Japan225^ 38.225,67 -119,88 -0,31% 21:34
WTI 82,70 -0,94 -1,12% 22:29
Brent 87,17 -0,82 -0,93% 22:29
EUR/USD 1,0722 +0,0026 +0,24% 23:09
BTC/USD 62.998,40 -1.048,53 -1,64% 23:09
Gold spot 2.335,87 -2,08 -0,09% 23:05
#/^ Index indications calculated real time, zie disclaimer
HOGE RENDEMENTEN OP DE IEX-MODELPORTEFEUILLES > WORD NU ABONNEE EN PROFITEER VAN MAAR LIEFST 67% KORTING!

Stijgers & Dalers

Stijgers Laatst +/- % tijd
Philips Koninklijke 25,540 +5,795 +29,35% 17:38
EXOR NV 105,100 +4,000 +3,96% 17:35
IMCD 144,100 +2,400 +1,69% 17:35
Dalers Laatst +/- % tijd
ASMI 596,400 -27,400 -4,39% 17:37
ADYEN NV 1.151,000 -28,600 -2,42% 17:36
BESI 127,250 -3,150 -2,42% 17:35

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront